Marinus Pharmaceuticals Inc
MRNS
Market Cap$98.05M
Close$
$12.31
2137.8% upside
Current Fair Value
2137.8% upsideUndervalued by 2137.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $98.05 Million |
|---|---|
| Enterprise Value | $111.05 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.63 |
| Beta | 1.14 |
| Outstanding Shares | 57,064,095 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.68 |
|---|---|
| PEG | 2.57 |
| Price to Sales | - |
| Price to Book Ratio | -0.28 |
| Enterprise Value to Revenue | 3.54 |
| Enterprise Value to EBIT | -0.91 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.5 |
| Debt to Equity | -0.83 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Marinus Pharmaceuticals Inc
69 employeesMarinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-chara...